Myeloma & Cell TherapyWORKSHOP

October 14-15, 2021

OSTRAVA

Bright talks for outstanding research

Partners

Organized by Organization committeeUniversity of OstravaBlood Cancer Research GroupCell Coolab Ostrava

University Hospital Ostrava

Michal Šimíček, Ph.D.Hana Šahinbegović

Renata ŠnaurováSandra Charvátová

Marcello Turi

XVI. Myeloma and IV.Cell Therapy Workshop 2021 OSTRAVAWelcome to for the

10:10

10:35

11:15

11:40

12:05

13:30

13:55

14:20

14:45

09:45

14 Oct 2021

OSTRAVAOctober 14-15, 2021

9:30

Closing remarks for the day

Coffee break

Lunch break

SOCIAL EVENT at “Hola bar & tapas”

9:45 SESSION I

11:15 SESSION II

Opening remarks - Roman Hájek and Michal Šimiček

Characterization of multiple myeloma by an integrative geno-transcriptomic approach:from the genomic architecture to its functional consequences Da Via' Matteo Claudio, University of Milan, Italy

New applications of next-generation flow cytometry in multiple myeloma Bruno Paiva, Center for Applied Medical Research, Spain

Next generation proteomics with drug sensitivity screening identifies sub-clonesinforming therapeutic and drug development strategies for multiple myeloma patients Despina Bazou, Mater Misericordiae University Hospital, Ireland

Microenvironment dysregulation in multiple myeloma: novel challengesand therapeutic opportunitiesCirino Botta, University of Palermo, Italy

Exosomes as key mediators in BM-MM crosstalk Eline Menu, VUB Brussels, Belgium

Stromal cell-centric bone marrow inflammation in multiple myelomaTom Cupedo, Erasmus MC Rotterdam, The Netherlands

13:30 SESSION IIIPathogenesis of extramedullary multiple myeloma: from resistance to identificationTereza Sevcikova, Blood Cancer Research Group, Czech Republic

New Immunotherapy targets in multiple myeloma clinical dataLuciano Costa - University of Alabama at Birmingham

Multiple myeloma genomic defining eventsFrancesco Maura, Sylvester Comprehensive Cancer Center, University of Miami, USA “Multiple myeloma genomic defining events”

Diagnosis, prognosis and therapy of immunoglobulin light chain amyloidosisMorie Gertz, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA

XVI. Myeloma and IV.Cell Therapy Workshop 2021

09:55

10:20

11:15

11:50

12:15

14:00

14:30

14:55

15:20

09:30

15 Oct 2021

12:40

OSTRAVAOctober 14-15, 2021

Closing remarks

Coffee break

Lunch break

11:15 SESSION VNew targets and technologies for CAR-T cell therapy Michael Hudecek, University of Würzburg, Germany

NK cells immunotherapy in multiple myelomaMonika Holubová, Fakultní nemocnice Plzeň, , Czech Republic

Delineating tumor heterogeneity in the era of novel immunotherapies in multiple myelomaLeo Rasche, Universty of Würzburg, Germany

Alternative RNA processing prospective RNA toolkit in myeloma cell therapySophia Adamia, Dana-Farber Cancer Institute, USA

14:00 SPECIAL SESSIONNew Therapies in MyelomaKenneth Anderson, Dana-Farber Cancer Institute, USA

9:30 SESSION IVFunctional precision medicine for biomarker discovery and treatment support of relapsed/refractory myeloma patients Caroline Heckman, Institute for Molecular Medicine Finland, Finland

Circulating plasma cells as critical diagnostic marker in the newly diagnosed multiple myelomaTomas Jelinek, Blood Cancer Research Group, Ostrava, Czech Republic

Connection between autophagy and oncogenic MyD88 signalingMarcello Turi, Blood Cancer Research Group, Czech Republic

CD19 promotor hypermethylation results in CD19 antigen-negative relapse to CAR-T cellsMichal Smida, Citec, Czech Republic

Allogenic CAR-T cellsPiotr Celichowski, Blood Cancer Research Group, Ostrava, Czech Republic

The role of NK cells in treatment of multiple myelomaMichael O'Dwyer, National University of Ireland, Ireland

14:30 SESSION VI

XVI. Myeloma and IV.Cell Therapy Workshop 2021